Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 43Neoplasms 13Neoplasm Metastasis 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × eribulin × Clear all
NCT04345913 2026-05-27

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
24 enrolled 24 charts
Breast

Triple Negative Breast Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Completed
27 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

Eisai Inc.

Phase 1/2 Completed
258 enrolled 18 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

Merck Sharp & Dohme LLC

Phase 3 Completed
622 enrolled 26 charts
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡